Fuentes Virginia Luis
Department of Veterinary Clinical Sciences, Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, AL9 7TA United Kingdom.
Vet Clin North Am Small Anim Pract. 2004 Sep;34(5):1145-55. doi: 10.1016/j.cvsm.2004.05.018.
Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure. It combines calcium-sensitizing effects with PDE III inhibition, resulting in positive inotropic effects and veno- and ergic signal transduction pathway in the failing heart, the calcium-sensitizing effects may assume greater importance in patients with heart failure. Clinical studies in human patients have shown sustained improvement in hemodynamics and exercise tolerance, with favorable neurohormonal effects. One study showed a nonsignificant trend toward increased mortality [20], but proarrhythmic effects have not ben observed. Studies in naturally occurring canine heart failure suggest that pimobendan's effects are at least comparable to those of ACE inhibitors, if not superior. Pimobendan is likely to play an increasing role in the future in the treatment of canine heart disease.
匹莫苯丹是一种口服强心扩血管复合药物，在许多国家可用于治疗犬类心力衰竭。它兼具钙增敏作用和磷酸二酯酶III抑制作用，从而产生正性肌力作用以及对衰竭心脏的静脉和动脉作用。在衰竭心脏的能量信号转导通路中，钙增敏作用对心力衰竭患者可能更为重要。针对人类患者的临床研究表明，其对血流动力学和运动耐量有持续改善作用，并具有良好的神经激素效应。一项研究显示死亡率有增加的趋势，但不显著[20]，且未观察到促心律失常作用。对自然发生的犬类心力衰竭的研究表明，匹莫苯丹的效果即便不优于血管紧张素转换酶抑制剂，至少也与之相当。匹莫苯丹未来在犬类心脏病治疗中可能会发挥越来越重要的作用。
